Icomix (Helium, Carbon Monoxide)

Helium’s very low density reduces turbulent flow, making it easier for air to move through narrowed airways. Carbon monoxide, at therapeutic low concentrations, activates the heme‑oxygenase pathway, which dampens inflammatory signaling in the respiratory tract. Together, these actions help open the airways and lessen inflammation.

The specific dose and administration parameters for Icomix are determined by the prescribing clinician based on the patient’s condition, severity, and response. Dosage is individualized and delivered via calibrated inhalation equipment under medical supervision.

Safety data for Icomix in pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the Icomix product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with standard oxygen therapy, Icomix offers the added benefit of reduced airway resistance due to helium’s low density, while low‑dose carbon monoxide provides anti‑inflammatory effects not present in pure oxygen. Unlike bronchodilator inhalers, it works primarily by physical and molecular mechanisms rather than receptor agonism.

Icomix cylinders should be stored at ambient temperature, in a well‑ventilated, dry location away from direct sunlight and heat sources. Keep cylinders upright, secure them to prevent tipping, and ensure the valve is closed when not in use. Follow all local regulations for medical gas storage.

Icomix is delivered via a calibrated inhalation system, such as a ventilator circuit or a specialized gas delivery mask, under the supervision of qualified healthcare personnel. The gas mixture is inhaled directly into the patient’s airway, and the duration of therapy is set by the prescriber.

Serious risks include carbon monoxide poisoning, methemoglobinemia, severe respiratory depression, and allergic reactions. Patients should be closely monitored for signs of hypoxia, chest pain, or unexplained neurological symptoms, and immediate medical intervention should be initiated if any serious adverse event occurs.

Icomix is contraindicated in individuals with known hypersensitivity to carbon monoxide, those with severe anemia, or patients who have a history of methemoglobinemia. It should also be avoided in patients where the risk of CO exposure outweighs potential benefits, as determined by the treating physician.